Toxic chemicals found in food and wine
The report found there has been a 'sharp increase' in pesticide and chemical residues in wine bottled since 2010. — TNS
A team of researchers has found 'alarmingly high' levels of trifluoroacetic acid (TFA), a so-called 'forever chemical', in dozens of organic and non-organic pastas, baked goods and breakfast cereals from Europe, as well as in wine.
'In conventional grain products, the average levels were so high that a health risk to children can no longer be ruled out,' said Helmut Burtscher-Schaden, an environmental chemist part of the Brussels-based Pesticide Action Network (PAN) Europe, which describes TFA as a 'product of PFAS pesticides and industrial chemicals.'
Forever chemicals, also known as PFAS, are thousands of long-lasting substances used in household and everyday products since the middle of the 20th century but which have been found to be difficult to remove from the environment and from human bodies.
The latest research points to 'widespread contamination from PFAS (per- and poly fluoroalkyl substances) pesticides,' PAN Europe said, warning that TFA tends to build up in water and farmland.
The amount of TFA in the food items was found to be three times that recorded in a similar study eight years ago, according to PAN Europe, which in April warned of 'dramatic rise' of TFA in wine.
In a report covering wines from Austria, Belgium, Croatia, France, Germany, Greece, Hungary, Italy, Luxembourg and Spain, PAN Europe found that while pre-1988 vintages do not contain any such contamination, there has been a 'sharp increase' in pesticide and chemical residues in wine bottled since 2010.
Such a 'steep accumulation' should be 'a red flag that calls for decisive action,' according to Michael Müller, a professor of pharmaceutical and medicinal chemistry at the University of Freiburg.
The European Chemicals Agency has warned that TFA 'may cause harm to the unborn child' and 'may impair fertility.' – dpa
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
Six million donkeys slaughtered for Chinese medicine: charity
ADDIS ABABA: Almost six million donkeys are slaughtered annually for Chinese medicine, with severe knock-on effects for African villagers who rely on the animals, a UK-based charity said on Thursday. It is driven by an increase in China's production of ejiao -- a product marketed as a health supplement that uses collagen from donkey skins -- which is a $6.8-billion industry, according to China-based research firm Qianzhan. China, whose donkey population has plummeted from 11 million in 1992 to 1.5 million in 2023, has turned to Africa to meet its demand. With donkey populations falling, the African Union issued a 15-year moratorium on donkey slaughter last year. UK-based charity The Donkey Sanctuary said 'the ejiao industry drives a massive global trade in donkey skins, much of it illegal'. It said around 5.9 million donkeys were killed worldwide last year. The ejiao trade is expected to require at least 6.8 million donkey skins by 2027. The rising value of donkeys means they have increasingly become targets for criminals. 'Traders exploit vulnerable people using large and sophisticated networks of agents to pressure donkey owners into selling their animals,' the charity said. 'Illegal networks operate across the continent, often without consequence, stealing and slaughtering donkeys in the night,' it added. 'Donkeys die in often unregulated, inhumane, and unsanitary conditions, and large numbers perish on their way to slaughterhouses,' it continued. The impact on humans is particularly felt by women and children, who rely on donkeys for farming activities such as ploughing and for carrying goods to market. The criminal operations also generated health risks, The Donkey Sanctuary said. 'The transportation of untreated skins and improper disposal of donkey carcasses risk triggering the spread of infectious diseases and damaging local ecosystems.'
The Star
a day ago
- The Star
Astronauts from India, Poland, Hungary launched on first space station mission
The Axiom-4 crew, Pilot Shubhanshu Shukla of India, Mission Specialist Tibor Kapu of Hungary, Commander Peggy Whitson of the U.S., and Mission Specialist Slawosz Uznanski-Wisniewski of Poland, react as they greet their family members before their mission to the International Space Station, in Cape Canaveral, Florida, U.S., June 24, 2025. REUTERS/Steve Nesius CAPE CANAVERAL, Florida (Reuters) -NASA retiree turned private astronaut Peggy Whitson was launched on the fifth spaceflight of her career early on Wednesday, joined by crewmates from India, Poland and Hungary heading for their countries' first visit to the International Space Station. The astronaut team lifted off from NASA's Kennedy Space Center in Cape Canaveral, Florida, at about 2:30 a.m. EDT (0630 GMT), beginning the latest mission organized by Texas-based startup Axiom Space in partnership with Elon Musk's rocket venture SpaceX. The four-member crew was carried aloft on a towering SpaceX launch vehicle consisting of a Crew Dragon capsule perched atop a two-stage Falcon 9 rocket. Live video showed the towering spacecraft streaking into the night sky over Florida's Atlantic coast trailed by a brilliant yellowish plume of fiery exhaust. It marked the first Crew Dragon flight since Musk briefly threatened to decommission the spacecraft after U.S. President Donald Trump threatened to cancel Musk's government contracts in a high-profile political feud between the two men earlier this month. Axiom 4's autonomously operated Crew Dragon was expected to reach the ISS after a flight of about 28 hours, then dock with the outpost as the two vehicles soar together in orbit some 250 miles (400 km) above Earth. If all goes according to plan, the Axiom 4 crew will be welcomed aboard the orbiting space laboratory Thursday morning by its seven current resident occupants - three astronauts from the U.S., one from Japan and three cosmonauts from Russia. Whitson, 65, and her three Axiom 4 crewmates - Shubhanshu Shukla, 39, of India, Sławosz Uznański-Wiśniewski, 41, of Poland, and Tibor Kapu, 33, of Hungary - are slated to spend 14 days aboard the space station conducting microgravity research. The mission stands as the fourth such flight since 2022 arranged by Axiom as the Houston-headquartered company builds on its business of putting astronauts sponsored by private companies and foreign governments into Earth orbit. For India, Poland and Hungary, the launch marked a return to human spaceflight after more than 40 years and the first mission to send astronauts from each of those three countries to the International Space Station. The Axiom 4 participation of Shukla, an Indian air force pilot, is seen by India's own space program as a kind of precursor to the debut crewed mission of its Gaganyaan orbital spacecraft, planned for 2027. The Axiom 4 crew is led by Whitson, who retired from NASA in 2018 after a pioneering career that included her tenure as the first woman to serve as the U.S. space agency's chief astronaut. She also was the first woman to command an ISS expedition and the first to do so twice. Now a consultant and director of human spaceflight for Axiom, she has logged a career total of 675 days in space, a U.S. record, during three NASA missions and a fourth flight to space as commander of the Axiom 2 mission in 2023. The Axiom 4 mission was previously scheduled for liftoff on Tuesday before a forecast of unsuitable weather forced a 24-hour postponement. (Reporting by Steve Nesius in Cape Canaveral, Florida, Steve Gorman in Los Angeles and Joey Roulette in Washington; Editing by Saad Sayeed)
Malaysian Reserve
a day ago
- Malaysian Reserve
Mark Hensley joins RBL LLC as a senior adviser
HOUSTON, June 24, 2025 /PRNewswire/ — RBL LLC, a pioneering biotech venture creation studio designed to rapidly build companies based on lifesaving medical technologies, today announced the addition of Mark Hensley as a senior adviser. Hensley will leverage his proven experience in biotech venture creation, corporate strategy and business development to accelerate the development and commercialization of breakthrough life sciences technologies at the Houston-based venture creation studio. With more than 15 years of experience in the biotechnology industry, Hensley brings a wealth of knowledge in company formation, venture financing, mergers and acquisitions and strategic partnerships. He has a proven track record of successfully identifying high-potential biotech opportunities and scaling new ventures across a variety of therapeutic areas, including transplant, immunology and rare diseases. 'Following our October launch, we expect Mark's impressive track record of leading large business transactions in the biotech industry, coupled with his deep expertise in strategic partnerships, to play an instrumental role in advancing our mission,' said Paul Wotton, CEO and managing partner of RBL LLC. 'As we continue launching cutting-edge biomedical innovations, we look forward to working with Mark's strategic guidance to drive the development of breakthrough therapies from the lab bench to the clinic.' 'Joining RBL LLC as it prepares for the launch of multiple promising clinical-stage biotech companies is a great opportunity,' Hensley said. 'I look forward to working alongside the talented team at RBL LLC to help identify and steer innovative Houston-based biotech ventures to success while fostering the strategic partnerships necessary to accelerate the development of therapies that will have a lasting impact on patients worldwide.' Hensley currently serves as chief operating officer at Heron Therapeutics, a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Prior to this role, he served as CEO of Veloxis Pharmaceuticals, where he led a major buy-side acquisition, expanding the company's global footprint in nephrology. As chief commercial officer at Veloxis, he played a pivotal role in executing a billion-dollar sell-side transaction, demonstrating his strategic vision and ability to drive substantial growth in the biotechnology sector. Hensley holds a Bachelor of Science in biology with a minor in chemistry from the University of North Texas, and his expertise spans a wide range of disciplines within the biotechnology and life sciences industries. About RBL LLC:RBL LLC is a pioneering biotech venture creation studio based in Houston that is dedicated to accelerating the development of breakthrough medical technologies and therapies through company formation. RBL provides entrepreneurs, researchers and innovators with infrastructure, financial support and strategic guidance as well as access to laboratory space and shared resources in the Texas Medical Center Helix Park. For more information, please visit Media Contact: Russo PartnersDavid Schull or Liz Phillips(347)
